This information is intended for use by health professionals
CONTAC Non Drowsy 12 Hour Relief
Each capsule contains Pseudoephedrine Hydrochloride 120 mg.
For excipients, see Section 6.1.
Prolonged-release capsule, hard
Clear gelatin capsule, with CONTAC ND printed in black ink and containing pink prolonged-release granules.
CONTAC Non Drowsy 12 Hour Relief is a decongestant of the mucous membranes of the upper respiratory tract, especially the nasal mucosa and sinuses and is indicated for the symptomatic relief of conditions such as allergic rhinitis, the common cold and influenza.
One capsule to be taken in the morning and another at bedtime.
Children under 12 years:
The healthy elderly may use an adult dose.
Route of administration:
Known hypersensitivity to pseudoephedrine hydrochloride or excipients. Individuals with severe hypertension or severe heart disease. Patients who are taking monoamine oxidase inhibitors (MAOI) or have taken them within the preceding two weeks. Patients receiving other sympathomimetics (such as decongestants, appetite suppressants and amphetamine-like psychostimulants).
CONTAC Non Drowsy 12 Hour Relief should be used with caution in patients suffering from mild to moderate hypertension, heart disease, arrhythmias, diabetes, hyperthyroidism, phaeochromocytoma, glaucoma and prostatic enlargement.
Caution should be exercised when using the product in the presence of moderate to severe renal impairment (particularly if accompanied by cardiovascular disease).
Ischaemic optic neuropathy
Cases of ischaemic optic neuropathy have been reported with pseudoephedrine.
Pseudoephedrine should be discontinued if sudden loss of vision or decreased visual acuity such as scotoma occurs.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
The following pack warnings and advice are recommended:
Do not chew or crush the capsule contents as this will interfere with the 12 hour action of the capsules.
If you are under the care of your doctor or receiving prescribed medicines or are pregnant or breast feeding, consult your doctor before taking this medicine.
Do not take with any other products for the relief of colds, congestion or hay fever.
If symptoms persist for more than 7 days consult your doctor.
Keep all medicines out of the reach and sight of children.
Warning. Do not exceed the stated dose.
This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 'sodium-free'.
Forms of Interaction
Co-administration with MAOI (or within 2 weeks of stopping MAOI) may lead to hypertensive crisis.
Concomitant use of CONTAC Non Drowsy 12 Hour Relief with tricyclic antidepressants, sympathomimetic agents (such as decongestants, appetite suppressants and amfetamine-like psychostimulants) or with monoamine oxidase inhibitors and furazolidone, which interfere with the catabolism of sympathomimetic amines, may occasionally cause a rise in blood pressure.
Because of their pseudoephedrine content, CONTAC Non Drowsy 12 Hour Relief may partially reverse the hypotensive action of drugs which interfere with sympathomimetic activity including bretylium, bethanidine, guanethidine, debrisoquine, methyldopa, alpha- and beta-adrenergic blocking agents.
Do not use product if pregnant or breast feeding without medical advice.
Patients should be advised not to drive or operate machinery if affected by dizziness.
The following adverse reactions have been reported with pseudoephedrine:
Common (>1/100 to <1/10): nervousness, insomnia
Uncommon (>1/1,000 to <1/100): agitation, restlessness
Rare (>1/10,000 to <1/1000): hallucinations (particularly in children)
Nervous System Disorders
Common (>1/100 to <1/10): dizziness
Frequency not known: Ischaemic optic neuropathy
Rare (>1/10,000 to <1/1000): tachycardia, palpitations,
Rare (>1/10,000 to <1/1000): increased blood pressure*
*Increases in systolic blood pressure have been observed. At therapeutic doses, the effects of pseudoephedrine on blood pressure are not clinically significant.
Common (>1/100 to <1/10): dry mouth, nausea, vomiting
Skin and subcutaneous tissue disorders
Rare (>1/10,000 to <1/1000): rash, allergic dermatitis*
*A variety of allergic skin reactions, with or without systemic features such as bronchospasm, angioedema have been reported following use of pseudoephedrine
Renal and urinary disorders
Uncommon (>1/1,000 to <1/100): dysuria, urinary retention**
**Urinary retention is most likely to occur in those with bladder outlet obstruction, such as prostatic hypertrophy.
As with other sympathomimetics pseudoephedrine overdose will result in symptoms due to central nervous system and cardiovascular stimulation e.g. excitement, irritability, restlessness, tremor, hallucinations, hypertension, palpitations, arrhythmias and difficulty with micturition. In severe cases, psychosis, convulsions, coma and hypertensive crisis may occur. Serum potassium levels may be low due to extracellular to intracellular shifts in potassium.
Treatment should consist of standard supportive measures. Beta-blockers should reverse the cardiovascular complications and the hypokalaemia.
ATC Code R01B A02.
Pseudoephedrine has direct and indirect sympathomimetic activity and is an orally-effective decongestant of the mucous membranes of the upper respiratory tract, especially the nasal mucosa and sinuses.
The product is a prolonged-release capsule presentation having a therapeutic action of up to 12 hours.
Pseudoephedrine is readily and completely absorbed from the gastrointestinal tract after oral administration, with no presystemic metabolism. Peak plasma levels are achieved after 1-2 hours. The plasma half–life varies from 4.3-7.0 hours in adults, but is shorter (3.1 hours) in children.
The volume of distribution ranges from 2.64 to 3.51 l/kg in both single and multiple dose studies.
There is little metabolism of pseudoephedrine in man with approximately 90% being excreted in the urine unchanged. Approximately 1% is eliminated by hepatic metabolism, by N-demethylation to norpseudoephedrine.
As a weak base, the extent of renal excretion is dependent on urinary pH. At low urinary pH, tubular resorption is minimal and urine flow rate will not influence clearance of the drug. At high pH (>7.0), pseudoephedrine is extensively reabsorbed in the renal tubule and renal clearance will depend on urine flow rate.
Hepatic disease is unlikely to affect the pharmacokinetics of the drug. Renal impairment will result in increased plasma levels.
There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.
Gelatin, sucrose, starch, ethylcellulose, oleic acid, medium chain triglycerides, ammonium hydroxide (E527), hypromellose, titanium dioxide (E171), macrogol, carminic acid (E120), shellac (E904), black iron oxide (E172), simeticone, soya lecithin (E322).
Do not store above 25°C.
Blisters of PVC 200 micron (polyvinylchloride)/PVDC 60 gsm (polyvinylidenechloride) backed with aluminium foil 20 micron, contained in a boxboard carton. Each pack contains 6 capsules.
Omega Pharma Ltd.
32 Vauxhall Bridge Road
LONDON, SW1V 2SA
4 September 2001